POLE2

POLE2 encodes the non-catalytic B-subunit of DNA polymerase ε, functioning as a structural scaffold and protein-interaction hub at the replication fork whose transcription is cell-cycle regulated through Sp1/E2F promoter elements and modulated by the HDAC10/SP1 acetylation axis and FOXM1 (PMID:11433027, PMID:37657752, PMID:35173608). Its C-terminal domain acts as a general NPF-motif receptor that recruits diverse nuclear partners—including TTF2, WDHD1, and DONSON—through a shallow binding pocket defined by residues Y513, E520, and S522, while its N-terminal region binds SAP18 to recruit Sin3/HDAC co-repressor activity for transcriptional repression [PMID:11872158, PMID:bio_10.1101_2025.03.17.643635]. During mitosis, TTF2 bridges TRAIP to POLE2, directing TRAIP-mediated ubiquitylation of the CMG helicase to trigger replisome disassembly and mitosis-specific DNA synthesis (MiDAS) [PMID:bio_10.1101_2024.12.01.626218]. In cancer contexts, POLE2 promotes proliferation through stabilization of FOXM1 via AURKA and of CD44 via MDM2 inhibition, and activates NRF2/GPX4-mediated ferroptosis resistance and PI3K/AKT signaling (PMID:35039475, PMID:38627379, PMID:38070189, PMID:40081544).

1. 2001 High

   Establishing how POLE2 transcription is cell-cycle regulated resolved the question of how a replication gene is coordinately expressed during S phase: the POLE2 promoter requires an Sp1 element for basal activity and two overlapping E2F sites for full serum-responsive induction, linking POLE2 expression to E2F-pocket protein complexes.

   Evidence Luciferase reporter assays, EMSA, and DNase I footprinting of the human POLE2 promoter

   PMID:11433027

   Open questions at the time

   • Whether E2F-mediated regulation is sufficient to explain POLE2 expression in all cell types
   • No chromatin-level (ChIP) confirmation of E2F occupancy in vivo at the time
2. 2002 Medium

   Demonstrating that POLE2's N-terminal region binds SAP18 and recruits HDAC activity revealed a non-replicative, transcription-regulatory function for a polymerase subunit, expanding the functional repertoire of replication machinery components.

   Evidence Yeast two-hybrid, co-immunoprecipitation, reporter assays with trichostatin A inhibition in mouse system

   PMID:11872158

   Open questions at the time

   • Interaction demonstrated in mouse; not confirmed in human cells
   • Endogenous target genes repressed by the POLE2–SAP18–Sin3/HDAC complex remain unidentified
   • No structural detail of the N-terminal SAP18-binding interface
3. 2022 Medium

   Placing POLE2 upstream of AURKA-mediated FOXM1 stabilization in glioblastoma established the first cancer-associated signaling axis through which POLE2 promotes tumor growth beyond its replicative role.

   Evidence shRNA knockdown, ubiquitination assays, and rescue experiments in glioblastoma cells in vitro and in vivo

   PMID:35039475

   Open questions at the time

   • Mechanism by which POLE2 influences AURKA activity is unknown
   • Not replicated outside glioblastoma
4. 2022 Medium

   Identifying FOXM1 as a direct transcriptional regulator of POLE2 expression created a potential FOXM1→POLE2→AURKA→FOXM1 feedback loop, though these findings come from separate cancer types.

   Evidence FOXM1 overexpression/knockdown with qRT-PCR and Western blot in lung adenocarcinoma cells

   PMID:35173608

   Open questions at the time

   • Direct promoter binding by FOXM1 not shown by ChIP
   • Whether a true feedback loop operates in any single cell type is untested
5. 2023 Medium

   Demonstrating that HDAC10 deacetylates SP1 to maintain SP1 binding at the POLE2 promoter connected epigenetic regulation to POLE2 expression and DNA damage repair, providing an upstream regulatory layer.

   Evidence shRNA knockdown, acetylation assay, ChIP, overexpression rescue, DNA damage assays in NSCLC cells

   PMID:37657752

   Open questions at the time

   • Whether SP1 acetylation status affects POLE2 expression in non-cancer contexts is unknown
   • Specific acetylation sites on SP1 not mapped
6. 2023 Medium

   Showing that POLE2 activates NRF2/GPX4 signaling to suppress ferroptosis in gastric cancer revealed a non-canonical role for POLE2 in regulating oxidative stress and cell death.

   Evidence Overexpression/knockdown, ferroptosis assays, rescue with NRF2/GPX4 silencing in gastric cancer cells

   PMID:38070189

   Open questions at the time

   • How POLE2, a replication factor, mechanistically upregulates NRF2 transcription or stability is unresolved
   • Single cancer type; no normal-tissue comparison
7. 2024 Medium

   Establishing that POLE2 stabilizes CD44 by reducing MDM2-mediated ubiquitination linked POLE2 to Rac signaling and osteosarcoma progression, showing POLE2 can modulate specific E3 ligase–substrate interactions.

   Evidence Ubiquitination assay, rescue epistasis with CD44 knockdown, in vitro and in vivo osteosarcoma models

   PMID:38627379

   Open questions at the time

   • Whether POLE2 directly interacts with MDM2 or CD44, or acts indirectly, is undetermined
   • Mechanism of MDM2 inhibition by POLE2 not established
8. 2024 High

   Reconstitution of the TTF2–TRAIP–POLE2 tripartite complex during mitosis answered how the TRAIP ubiquitin ligase is targeted to the replisome: TTF2 bridges phosphorylated TRAIP to POLE2, directing CMG helicase ubiquitylation for replisome disassembly and MiDAS.

   Evidence Biochemical reconstitution, domain mapping with zinc-finger and POLE2-binding-motif mutants, ubiquitylation assay (preprint)

   PMID:bio_10.1101_2024.12.01.626218

   Open questions at the time

   • Awaits peer-reviewed publication
   • In vivo validation of TTF2-POLE2 interaction requirements for MiDAS not yet shown in mammalian cells
   • Whether other NPF-containing partners compete with TTF2 for POLE2 binding during mitosis is unknown
9. 2025 High

   Identifying POLE2's C-terminal pocket as a general NPF-motif receptor that binds multiple nuclear partners (TTF2, WDHD1, DONSON, SYNJ1) resolved the structural basis of POLE2's role as a protein-interaction hub at the replication fork.

   Evidence Native holdup assay, quantitative binding measurements, mutagenesis of Y513/E520/S522, AlphaFold modeling, proteome-scale screen (preprint)

   PMID:bio_10.1101_2025.03.17.643635

   Open questions at the time

   • Awaits peer-reviewed publication
   • Crystal or cryo-EM structure of the NPF-POLE2 complex not yet available
   • Functional consequences of individual NPF-partner recruitment at the fork remain to be dissected
10. 2025 Medium

    Demonstrating that GINS4 binds POLE2 and signals through PI3K/AKT extended the replication-complex interactome of POLE2 and linked it to a growth-signaling pathway in hepatocellular carcinoma.

    Evidence Co-immunoprecipitation, lentiviral knockdown/overexpression rescue, Western blot, xenograft model in HCC

    PMID:40081544

    Open questions at the time

    • GINS4–POLE2 interaction initially predicted computationally; single reciprocal Co-IP
    • Whether PI3K/AKT activation is a direct or indirect consequence of the GINS4–POLE2 axis is unknown

• Key unresolved questions include how POLE2's NPF-motif receptor function is regulated during the cell cycle (partner switching), how POLE2 influences signaling pathways (NRF2, PI3K/AKT, Wnt) outside its replication role, and whether the non-replicative cancer phenotypes reflect physiological functions or neomorphic activities.
• No structural determination of the full-length POLE2 in complex with Pol ε holoenzyme and NPF partners
• Mechanism connecting POLE2 to transcription factor or E3 ligase regulation remains indirect in all cancer studies
• Whether POLE2's NPF-binding and SAP18-binding functions are coordinated or mutually exclusive is untested